(1) Novavax, Inc. (NASDAQ:NVAX) triggered: 09/30/2014
Novavax is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. Co.'s vaccine technology platform is based on proprietary recombinant nanoparticle vaccine technology that includes virus-like particles and protein nanoparticle vaccine candidates. Co.'s vaccine product pipeline targets a range of infectious diseases with candidates in clinical development for respiratory syncytial virus, seasonal influenza, and pandemic influenza. Further, CPL Biologics Private Limited, Co.'s joint venture company in India, is developing a number of vaccine candidates that were genetically engineered by Co.
Any ideas and opinions presented in all Market News Video clips are for informational and educational purposes
only, and do not reflect the opinions of BNK Invest, Inc. or any of its affiliates, subsidiaries or partners.
In no way should any content contained herein be interpreted to represent trading or investment advice.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. Read Full Disclaimer.